Core Laboratories (CLB) Lifted to Buy at ValuEngine
ValuEngine upgraded shares of Core Laboratories (NYSE:CLB) from a hold rating to a buy rating in a research report sent to investors on Tuesday.
Several other equities analysts have also recently issued reports on CLB. Citigroup upgraded Core Laboratories from a sell rating to a neutral rating and set a $117.00 price target on the stock in a report on Monday, August 13th. Piper Jaffray Companies reiterated a hold rating and issued a $96.00 price target on shares of Core Laboratories in a report on Friday, July 27th. ABN Amro cut Core Laboratories from a hold rating to a sell rating in a report on Monday, July 2nd. Edward Jones initiated coverage on Core Laboratories in a report on Tuesday. They issued a buy rating on the stock. Finally, Zacks Investment Research cut Core Laboratories from a buy rating to a hold rating in a report on Wednesday, May 16th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company. The stock has an average rating of Hold and an average target price of $114.90.
Shares of CLB stock opened at $107.98 on Tuesday. The firm has a market capitalization of $4.91 billion, a P/E ratio of 53.99, a PEG ratio of 3.81 and a beta of 1.50. Core Laboratories has a one year low of $87.66 and a one year high of $130.34. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.24 and a quick ratio of 1.85.
The business also recently announced a quarterly dividend, which was paid on Monday, August 13th. Shareholders of record on Monday, July 23rd were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.04%. The ex-dividend date was Friday, July 20th. Core Laboratories’s dividend payout ratio (DPR) is currently 110.00%.
A number of institutional investors and hedge funds have recently modified their holdings of CLB. Fisher Asset Management LLC bought a new position in Core Laboratories during the first quarter worth about $47,402,000. Massachusetts Financial Services Co. MA boosted its holdings in Core Laboratories by 24.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,787,251 shares of the oil and gas company’s stock worth $193,416,000 after buying an additional 351,847 shares during the last quarter. WCM Investment Management CA lifted its holdings in shares of Core Laboratories by 5.1% during the 1st quarter. WCM Investment Management CA now owns 5,035,827 shares of the oil and gas company’s stock valued at $544,977,000 after purchasing an additional 242,096 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Core Laboratories by 9,329.6% during the 2nd quarter. Millennium Management LLC now owns 226,594 shares of the oil and gas company’s stock valued at $28,598,000 after purchasing an additional 224,191 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Core Laboratories by 40.1% during the 1st quarter. Sei Investments Co. now owns 638,723 shares of the oil and gas company’s stock valued at $69,123,000 after purchasing an additional 182,848 shares in the last quarter.
Core Laboratories Company Profile
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Featured Story: How to Invest in an Index Fund
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.